CD8A and neoplasm: IPA further enhances the anti-tumor immune response by increasing H3K27 acetylation in the Tcf7 super enhancer region, modulating the dry program of CD8+ T cells, and promoting the production of depletion precursor CD8+ T cells (Jia et al., 2024).